BTX 1204 Atopic Dermatitis Study Results Presentation

Published: Jun 07, 2018

Philadelphia PA and Sydney Australia, 7 June 2018 -- Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, "Botanix" or "The Company") is pleased to release a presentation containing supplementary information on the BTX 1204 atopic dermatitis Phase lb study results.

Key highlights

  • Study data indicated BTX 1204 was twice as effective over the vehicle with substantial improvement in the key signs of atopic dermatitis
  • BTX 1204's efficacy still increasing at the 4-week timepoint, suggesting a longer treatment period enables BTX 1204 to potentially exceed industry performance
  • Achieved clear separation from vehicle, with BTX 1204 showing superiority over vehicle at an early stage of the treatment period
  • BTX 1204 demonstrated an excellent safety profile allowing for extended dosing, which remains a key challenge for other available therapies

Botanix Executive Director Matt Callahan said: "We are extremely pleased with the results of our BTX 1204 atopic dermatitis study after a relatively short treatment period of just 4-weeks. There is potential for BTX 1204 to exceed the performance of other products over a longer treatment period, given efficacy was still increasing at the end of the treatment period along with the excellent safety profile demonstrated by BTX 1204. Further, the substantial reduction in key signs of atopic dermatitis, provides us with the confidence that the unmet needs of itch and underlying inflammation can be addressed."

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company's focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of PermetrexlM on both a fee-for-service and traditional license basis.

Back to news